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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortali-
ty worldwide. Comorbidities are often reported in patients with COPD and may influence the
cost of care. Yet, the extent by which comorbidities affect costs remains to be determined.
Objectives
To review, quantify and evaluate excess costs of comorbidities in COPD.
Methods
Using a systematic review approach, Pubmed and Embase were searched for studies ana-
lyzing excess costs of comorbidities in COPD. Resulting studies were evaluated according
to study characteristics, comorbidity measurement and cost indicators. Mark-up factors
were calculated for respective excess costs. Furthermore, a checklist of quality criteria
was applied.
Results
Twelve studies were included. Nine evaluated comorbidity specific costs; three examined
index-based results. Pneumonia, cardiovascular disease and diabetes were associated
with the highest excess costs. The mark-up factors for respective excess costs ranged be-
tween 1.5 and 2.5 in the majority of cases. On average the factors constituted a doubling of
respective costs in the comorbid case. The main cost driver, among all studies, was inpa-
tient cost. Indirect costs were not accounted for by the majority of studies. Study heteroge-
neity was high.
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Conclusions
The reviewed studies clearly show that comorbidities are associated with significant excess
costs in COPD. The inclusion of comorbid costs and effects in future health economic evalu-
ations of preventive or therapeutic COPD interventions seems highly advisable.
Background
Chronic obstructive pulmonary disease (COPD) causes around 5.6% of global deaths and pres-
ently constitutes the third leading cause of death, after stroke and ischemic heart disease,
worldwide [1]. The persistent airflow limitation is associated with chronic inflammation in
the airways, which is mediated by an increased expression of pro-inflammatory cytokines,
chemokines, adhesion molecules, enzymes and receptors [2, 3]. The causes for COPD include
environmental, as well as genetic factors. In developed countries the biggest risk factor for de-
veloping COPD is past or present smoking [4]. Around 15.4% of active smokers and 10.7% of
ex-smokers are afflicted by COPD [5]. Not knowing if epithelial barrier dysfunction is cause or
consequence of COPD, chemicals in tobacco smoke lead to down-regulation of tight junction
genes [6] and promote dysregulation of the pulmonary epithelial barrier [7]. On the genetic
side, alpha-1 antitrypsin (A1AT) deficiency is a significant risk factor but only accounts for
around 2% of COPD cases [8]. The severity of COPD, among other factors, seems to correlate
with a decreased diversity of the bronchial microbiome, as well as the presence of potentially
pathogenic microorganisms and an increase of functions connected to pathogen-based inflam-
mation [9–13]. The prevalence of multimorbidity among patients with COPD is significantly
higher, than in patients without the disease [14–16]. Allocating causality between COPD and
comorbidities is still difficult [17–19]. The reason for the increase and its influence on survival
is not quite understood but in addition to shared risk factors like smoking and reduced physical
activity, evidence is pointing towards a systemic inflammatory nature of COPD [20–24]. A
shared component hypothesis, as proposed by network medicine, is currently evolving along-
side technological progress [17, 25–28]. Aging [29] and increased survival into old age consti-
tute congruent risk factors for developing COPD as well as comorbidities [30]. This co-
occurrence generates significant costs but also offers reasonable leverage points to facilitate im-
proved care, by either trying to prevent the development of specific comorbidities or by reduc-
ing their detrimental and often mutually reinforcing negative consequences. Strict study
eligibility criteria often exclude COPD patients with comorbidities and therefore may fail to ac-
count for clinical reality [31]. The aim of this review is to accumulate latest evidence on the
proportion and distribution of comorbid excess costs in COPD.
Methods
Definition of comorbidity
The debate about the definition of comorbidities is ongoing. One widely accepted position con-
stitutes comorbidity as the occurrence of an index disease as well as at least one distinct addi-
tional entity in one person, while the term multimorbidity implies the occurrence of multiple
acute or chronic diseases within one person but no index disease [32]. Some authors [33] re-
quire the index disease to cause the comorbidity and label diseases caused by perturbations of a
shared cellular network or molecular pathway as multimorbidities. Cost results may thus de-
pend upon whether or not comorbidities are required to interact with the index disease [34].
Comorbid Excess Costs in COPD
PLOSONE | DOI:10.1371/journal.pone.0123292 April 13, 2015 2 / 17
Yet, it may be difficult to specify, if a single disease is casually implicated in another disorder
[17]. Comorbidity in this study therefore refers to the “classical”meaning in which COPD con-
stitutes the index-disease and any additional disease affecting the same patient is labeled
as comorbidity.
Comorbidity assessment, costs and mark-up factors for COPD
Comorbidities can be assessed as single entity or as index. The index can either be quantitative
e.g. patients are evaluated by the sole number of their comorbidities, or it can be weighted. In a
weighted index, comorbidities with certain attributes e.g. a higher predictive mortality rate re-
ceive higher scores, whereas comorbidities with lower or no significant influence get reduced
scores or are not considered at all. A widely used and well-accepted weighted tool is the Charl-
son Comorbidity Index (CCI) [35] as well as its ICD-9 based modification, the Charlson Deyo
Index (CCI-Deyo) [36]. Conditions can receive scores of 1, 2, 3 or 6 and these are summed up
to estimate mortality. Single assessment studies can also use indices to characterize and match
study populations. In contrast to index-only studies however, they calculate the outcome for
single comorbid conditions and therefore enable a comorbidity specific understanding of the
respective cost influence.
This review only considered studies that directly stated or allowed the calculation of excess
costs. Cost differences are expressed as mark-up factors which were calculated by dividing
costs per patient in the comorbid case through costs per patient in the respective base case. Ad-
vantages of mark-up factors include their supplementary role alongside excess costs regarding
the proportional change of the base case. For comparability, study costs were inflated by the na-
tional consumer price indices and converted to 2013 USD using gross-domestic product pur-
chasing power parities [37–39]. Study quality was assessed independently by two reviewers
using a criteria list derived from three assessment frameworks [40–42]. Possible study bias was
reduced by separately stating comorbidity specific excess costs and by discussing respective re-
sults as well as limitations subsequently.
Data sources, search strategy and study selection
Data extraction methods and the search strategy were conceptualized by two authors. A litera-
ture search was conducted by using the PubMed and Embase database. Results in languages
other than English or German were excluded; a filter was set for journal articles. Reviews and
conference abstracts were only used as supplementary information. The PubMed search in-
cluded two separate passes. One was based on MeSH terms and the other was a standard free
search with Boolean operators. MeSH-search terms included: (("Pulmonary Disease, Chronic
Obstructive"[Mesh]) AND ("Costs and Cost Analysis"[Mesh] OR "Economics"[Mesh]) AND
"Comorbidity"[Mesh]). 81 results were returned. The free search included: (COPD) AND (cost
OR economic) AND comorbid and resulted in 298 hits. The free-search included all results
from the MeSH pass. An additional search was conducted by using Embase and applying the
filter for journal articles. The search was based on the following subject headings connected by
an “AND” operator: chronic obstructive lung disease, comorbidity, “health care cost”. 107
items were found.
Data extraction
After removing duplicates and studies which did not meet the language requirement, the re-
sults were screened, first by title, then by abstract. The abstracts were analyzed for keywords
and content. The full text was acquired for studies deemed potentially relevant and a final deci-
sion regarding inclusion was made. The study selection process is illustrated by Fig 1, the
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PRISMA checklist can be found as S1 PRISMA Checklist. Due to a lack of costs, studies de-
scribing only healthcare utilization were excluded. While utilization is a good indicator, costs
have the advantage of delivering a clear monetary picture of how comorbidities transform into
economic burden. After removing duplicates, screening title plus abstract and conducting a full
text analysis for the remaining results, twelve studies [43–54] remained. The selected terms of
interest regarding data extraction were mainly based on well accepted items used throughout
literature and other systematic reviews. Comorbid costs were the main focus of interest. Mark-
up factors were calculated after the respective costs were extracted.
Fig 1. Literature search and study selection process.
doi:10.1371/journal.pone.0123292.g001
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Results
A summary of key study parameters, as well as results and mark-up factors is given in Table 1.
Eight studies are located in the USA, and one each in Germany [51], Spain [54], Israel [53] and
Italy [52]. Nine studies were published in 2009 or subsequently, the earlier ones are from 2006
[44], 2003 [52] and 2001 [50]. Most studies incorporate outcomes via comorbidity-specific as-
sessment, only three incorporate outcomes based on binary presence or sole number of comor-
bidities [50, 52] or odds ratios (OR) for being in the upper 25, “most costly”, patient percentile
[53]. The sample size differs significantly among studies and reaches from 99 patients with
COPD and anemia [49] to 84,130 patients each for a group of COPD patients with or without
pneumonia [45]. Five studies [44, 46, 48–50] used routine data located entirely or partly in the
Medicare and Medicaid environment; the rest utilized routine or survey data from other
sources. To control for differences between groups with and without comorbidity, three studies
focused on pneumonia as comorbid disease [45, 47, 48], two studies focused on cardiovascular
disease (CVD) [43, 54], one on anemia [44], one on sleep apnea syndrome [49] and two on
multiple comorbidities [46, 51]. The rest focused on index-based outcomes. Four studies [43,
45, 47, 48] used Propensity Score Matching to adjust for patient heterogeneity; three studies
[44, 53, 54] used multiple regression analysis and three studies [46, 49, 51] just matched for
standard parameters including age, sex and comorbidities. The prevalent gender is female in
half of the studies. The mean age is around or above 70 years in six studies [44, 45, 48, 50, 53,
54] and lower than 50 years in two [46, 47]. Three studies performed lung function tests to di-
agnose COPD and classify COPD severity by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) definition [51, 53] or by the Spanish Society of Pneumology and Tho-
racic Surgery criteria in one study [54]. One study [52] used self-reported COPD diagnosis
without severity classification. Due to a lack of COPD severity information in most of the uti-
lized routine data, it could not be assessed or was not assessed in most of the studies. Two stud-
ies [43, 44] incorporated the utilization of oxygen therapy as indicator for severe cases of
COPD.
The existence of comorbid diseases was accounted for in every study either by assessing the
CCI or CCI-Deyo score and/or by directly stating the prevalence of specific comorbidities in
each group. The most prevalent comorbidities, in studies where this information was available,
were circulatory diseases with a prevalence reaching from 25% to over 50% [44, 46, 48, 50, 54],
as well as diabetes with a prevalence reaching from around 10% to 30% [44, 46, 48, 51, 54]. The
CCI or CCI-Deyo scores differed significantly among studies and ranged from around 0.4 [47]
to over 3 [45, 49, 53] in both groups respectively. Costs were reported in USD or EUR. The
evaluated cost categories were partially identical among studies and had a clear focus on all-
cause direct healthcare costs. Exceptions were the study by Dalal et al. 2011 [43], which distin-
guished between all-cause and COPD-related costs, as well as Polsky et al. 2012 [47], who in-
corporated indirect costs in the form of work absenteeism and short-term disability. Direct
costs, if subdivided, consisted of inpatient costs, outpatient costs as well as prescription costs.
This overall breakdown was done by seven studies [44, 45, 47, 49, 50, 53, 54]. Physician visits
in studies from the United States resemble appointments outside of hospitals but not within
hospital practices. The base case of COPD without comorbidity of interest differs significantly
among studies. Four studies state figures from around 10,000 USD to 16,000 USD for total di-
rect costs per patient and year [43, 45–47]. Halpern et al. 2006 [44] calculated a significantly
smaller annual base case in the range of around 2,200 USD per patient. Three other studies [49,
53, 54] also calculated relatively low base cases. On the contrary, Polsky et al. 2013 [47] reached
the highest base case of the studies under review, of around 28,300 USD. This high figure can
partly be attributed to the inclusion of productivity losses. The ratio of inpatient to outpatient
Comorbid Excess Costs in COPD


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comorbid Excess Costs in COPD









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comorbid Excess Costs in COPD











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comorbid Excess Costs in COPD
PLOSONE | DOI:10.1371/journal.pone.0123292 April 13, 2015 8 / 17
costs in the base case differs among studies. While inpatient costs are around 5 to 40 times
higher than outpatient costs in the studies for anemia and Sleep Apnea Syndrome (SAS) [44,
49], the inpatient base costs for pneumonia are around half the size of outpatient base costs, in
the respective studies for pneumonia [45, 47]. The prescription costs for pneumonia are
around 3,400 USD per patient and year. Taking into account the comorbid case, a strong
growth of inpatient costs can be observed. The respective mark-up factors increased to around
2.5 for anemia [44] and to around 3.4 [47] or 4.7 [45] in pneumonia, while the mark-up factors
for outpatient costs increased to about 1.6, 2.0 and 1.9 respectively. In contrast to this develop-
ment, the inpatient costs for SAS had a mark-up factor of 1.8, while outpatient costs more than
quintupled in the same case [49]. Compared to the base case, comorbid direct costs increased
among all studies. Renal and liver diseases created excess costs of 4,800 USD and 6,100 USD re-
spectively [51]. The lowest increase of total excess costs for a single comorbidity could be seen
for heart disease in Spain [54], comorbid anemia [44] as well as hypertension and diabetes
without complications [46], while the highest increase of 25,110 USD [45] or 24,249 USD [48]
or 25,419 USD [47] per patient and year could be observed for pneumonia.
An evaluation of basic quality criteria of all studies under review is illustrated in Table 2.
The study perspective could be inferred or was directly stated in the majority of studies, other
quality criteria like study limitations, source of funding and conflicts of interest were nearly al-
ways included. Funding through pharmaceutical companies was present in some studies. Pa-
rameters pertaining disease severity or prevalence of comorbidities or matching of patient
groups were more heterogeneous. Inclusion criteria were stated in all studies; only Polsky et al.
[47] focused on pneumonia patients and therefore did not state inclusion criteria for COPD pa-
tients. Assessment of study quality revealed significant heterogeneity in basic approaches and
methods of analyzing comorbidity while transparency of reporting seemed adequate.
Discussion
Among all studies analyzed in this review, comorbidities in COPD were associated with signifi-
cant excess costs (Figs 2 and 3).
On average, the mark-up factors resemble a doubling of costs in the comorbid case. There
were differences however, in the comorbidity-specific contributory extent. Pneumonia has
been investigated most intensively and found to cause very high direct and indirect costs, not
only in the base case, but especially as comorbidity in COPD. The pneumonia mark-up factors
for total direct costs range between 1.9 and 2.5, while inpatient mark-ups peak at 3.39 and 4.72
respectively. In order to reduce excess costs, the implications of inhaled corticosteroid treat-
ment for pneumonia risk in COPD patients [55, 56], the effect on inflammation markers [57,
58] as well as the usage in certain clinical COPD phenotypes [59] require further research.
Clarification of when to apply inhaled-corticosteroids is still needed [60]. After pneumonia,
CVD was connected to the second highest direct excess costs in one study [43]. Interestingly,
age>65 years, severe COPD and comorbid Congestive Heart Failure (CHF) seem to also be as-
sociated with an increased risk for community-acquired pneumonia [61]. Beta blockers, one of
the most important classes of drugs used to treat heart disease, may cause bronchoconstriction
in patients with obstructive airway diseases [62]. Under-use of beta blockers in heart disease
patients with COPD is documented [63]. However, looking at recent evidence, especially selec-
tive beta blockers show a good safety profile in patients with COPD and do not seem to be con-
nected to increased all-cause mortality or exacerbations [64–68]. The GOLD document
acknowledges these findings by stating that the potential benefits outweigh the risks [69]. From
a differentiated perspective, this is one example where comorbidities and therapy are linked
and interaction with cost is present. Total annual direct costs were 135% higher in patients
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with COPD and CVD, than in patients with COPD only, while COPD related costs were 38%
higher in the concomitant group [43]. In the same study all-cause excess costs for comorbid
CVD are around 16,800 USD per patient and year, while the mark-up factor reaches 2.35. Lin
et al. 2010 [46] provide annual excess costs of around 4,900 USD for COPD and CHF which
only transforms into a mark-up of 1.35. Contrary to these results, Miguel-Díez et al. [54] only
reach excess costs of 2,300 USD in a Spanish setting. However, this still resembles a mark-up
factor of 1.7. In another study [53] myocardial infarct and CHF increase the OR of being in the







































Purpose of the study
explained?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ⊠ ✓ ✓
Setting and location
stated?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Study perspective stated
directly or indirectly?
✓ ✓ ✓ ✓ ✓ ⊠ ✓ ⊠ ✓ ✓ ✓ ✓
Epidemiological sources
carefully described?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Were inclusion criteria
for patient groups clear
and sufficient?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was the severity of
COPD assessed or
indicated?
✓ ✓ ⊠ ⊠ ✓ ✓ ⊠ ⊠ ⊠ ✓ ✓ ⊠













✓ ⊠ ✓ ✓ ⊠ ⊠ ✓ ✓ ⊠ ⊠ ✓ n.a.
Did the outcome include
direct costs?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Did the outcome include
indirect costs?
⊠ ✓ ⊠ ⊠ ⊠ ✓ ✓ ⊠ ⊠ ✓ ⊠ ✓
Was the price date
stated?
✓ ✓ ⊠ ✓ ✓ ⊠ ✓ ✓ ⊠ ⊠ ✓ ✓
Were study limitations
stated?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ⊠ ✓ ✓
Was the source of
funding stated?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ⊠ ⊠ ⊠ ✓ ✓
Were possible conflicts
of interest stated?
✓ ✓ ✓ ⊠ ⊠ ✓ ✓ ✓ ⊠ ✓ ⊠ ✓
✓: Yes; ⊠: No; n.a.: not applicable; : unknown
1: Items partly based on Husereau et al. [40], McKeage et al. [41], Molinier et al. [42]
doi:10.1371/journal.pone.0123292.t002
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most costly quartile to around 6 (p< 0.001) and 7 (p = 0.001) respectively. In concordance, the
co-existence of COPD and CVD increases the risk for hospitalization due to exacerbations and
significantly reduces quality of life [70].
Evidence for the remaining comorbidities can only be drawn from a single study each. De-
pending on severity and presence of complications, the excess medical costs for comorbid dia-
betes were around 3,150 USD and 10,050 USD, the latter having a mark-up of 2.18 [46].
Unfortunately, despite its prevalence and importance [71], no additional studies stated num-
bers for diabetes. A smaller but also significant cost increase of around 2,700 USD excess costs
can be seen for COPD and anemia. Mark-up factors for anemia reach from 2.30 to 2.52 for in-
patient payments and inpatient claims respectively. An association between anemia and in-
creased risk of mortality seems likely [44]. Peptic ulcer, liver disease and AIDS have mark-up
factors of 1.99, 1.73 and 1.42 respectively [23]. In all three diseases the medical costs in the co-
morbid case are relatively high and range between around 17,000 USD and 18,500 USD. Sleep
apnea had excess costs of 5,381 USD [49] and reached the highest mark-up factor among all
studies and cost types of 5.61, for outpatient costs. Inpatient excess costs of 4,587 USD were
still around 7 times higher, than outpatient excess costs in this case. Not surprisingly, the sole
presence of one or more comorbidities is connected to higher excess costs [50, 52]. This is also
true in the general context, where a clear association between number of chronic diseases and
healthcare utilization as well as costs can be seen [72]. Interestingly, among all studies with
available data, inpatient costs in the comorbid case were always the main cost driver. This find-
ing is also confirmed by a recent study from Jansson et al. 2014 [73], who stated that by
Fig 2. Comorbidmark-up factors for total costs.
doi:10.1371/journal.pone.0123292.g002
Fig 3. Comorbidmark-up factors for medical costs.
doi:10.1371/journal.pone.0123292.g003
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amounting to 46% of total costs, hospitalization due to comorbid conditions is the main cost
driver among Swedish patients with COPD. Lowering inpatient utilization, by preventing pos-
sible drivers, like exacerbations in the case of COPD and CVD, should therefore constitute a
main field of interest in order to reduce excess costs in these cases. Timely updated treatment
guidelines may help to synchronize availability of latest evidence and their realization in the
clinical practice. The GOLD-guidelines account for respective treatment implications by con-
taining a full chapter on comorbidities in COPD [69]. Clear treatment advice is given for the
comorbidity alongside COPD and regarding COPD alongside the comorbidity. We agree with
Lehnert et al. [72, 74], who concluded that disease guidelines often fail to account for multi-
morbidity, and we would thus recommend the revision and updating of outdated disease
guidelines regarding clear treatment advice in the presence of specific comorbidities.
Results for indirect costs were stated by three studies but differed significantly. Polsky et al.
2012 [47] stated that indirect costs were around 27% of total cost. Miguel-Díez et al. 2010 [54]
only included sick leave days for indirect cost. As a consequence of this constraint and mostly
retired study participants, indirect costs only were 1.3% of total costs in this case. The same rea-
son could also apply to Dal Negro et al. 2003 [52], who stated indirect costs to be 3.6% of total
costs. A recent review showed that with inclusion of morbidity or mortality costs, indirect costs
constitute a substantial economic burden in COPD and range from 27% to 61% of total costs,
depending on study population [75].
There were limitations of the studies under review. The overall study heterogeneity was
high, not only because studies evaluated different comorbidities and different cost types but
also because they used different data sources. Due to used routine data, the prevalent gender
was female in half of the studies, despite the fact, that COPD universally is more prevalent in
men [5]. The studies also stated different patient characteristics and failed to assess the severity
of COPD and comorbidities in the majority of cases. Standardization of respective studies
would enable better comparability. It became apparent, that the severity of comorbidities is
currently mainly accounted for by using indices, which fail to address severity increments of
several illnesses. Unless routine data starts to contain information about the severity of COPD
and other diseases, cohort based study designs may have advantages in this regard. General
limitations of the used routine data in the studies under review were misclassifications and
non-generalizability of results due to predominance of specific populations e.g. low-income
minorities [44–49, 53]. The implementation of standards pertaining baseline characteristics of
patients as well as analysis seems warranted.
There are limitations of this review, too. In order to reduce heterogeneity, it was not actively
searched for studies, which consider COPD as the comorbidity and other diseases as index dis-
ease. An in-depth comparison of costs among different countries and different healthcare sys-
tems is highly challenging [76]. Rather than detailing costing techniques, this study
emphasized on the comparison of study approaches, offered conversion of cost results, and fo-
cused on the evaluation of excess costs and mark-up factors. Inferring whether these costs were
justified or not, was not possible. Deducing the total economic burden per comorbid disease or
drawing specific conclusions regarding the direct economic influence of COPD stage and co-
morbidity severity was not possible. Quality of life and mortality were not accounted for. It
seems recommendable doing so in a further review since for example heart disease seems to
have a strong detrimental influence on quality of life in COPD [77, 78]. A strength of this re-
view is the aggregated tabular illustration of costs and mark-up factors for comorbidities in
COPD. To our knowledge this has not been done before and helps to draw attention to eco-
nomic leverage points of COPD.
From a health economic perspective the pressure for including comorbidities in economic
evaluations of COPD interventions seems to mount. It is apparent, that due to complexity and
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heterogeneity of human disease and the real world setting it may be very difficult to transform
the possible interconnectedness of disease into economic models. Therefore, evaluating the
economic effect of comorbidity may still need to be handled irrespective of deciphering cause
and effect or molecular connection. However, systems biology and network medicine are cur-
rently giving rise to a more advanced perspective of human disease, which may also enable
more accurate health economic evaluations in the future. The human diseasome [79] (a plat-
form linking disease phenotypic features with known disease genes) as well as its supplement,
the interactome [25] (a platform linking disease with protein interactions) offer new ways to
understand COPD and comorbidities. Both help to unravel and illustrate the interconnected-
ness of multimorbidities but challenge the current understanding of disease classification. Bar-
basi et al. [25] state that following recent evidence it would be difficult if not counter-intuitive,
to consider human diseases as invariably independent. In concordance with this theory Grosdi-
dier et al. [26] conclude that 16 “COPD multimorbidities” all share significant numbers of
genes, proteins and biological pathways, which are targets of at least one chemical found in to-
bacco smoke. The current reductionist paradigm, where human disease and multimorbidity
are viewed and classified as more or less isolated entities, does not account for an advanced and
integrative shared component hypothesis [17, 25–28]. In addition to this, the very high failure
rate of drug candidates in the prevailing “one disease, one target, one drug” paradigm seems to
support this notion [80, 81]. The hurdles of regulation towards the co-development of drugs
are still high but slowly accounted for by regulation authorities [82, 83]. Ignoring or not recog-
nizing the economic implications of comorbidities in COPD will likely fail to target the true
costs of the disease and the possible underlying disease network. In addition to this the overall
effectiveness of respective multimorbid prevention and intervention methods will likely
be underestimated.
Conclusion
Acknowledging the accumulated data, comorbidities have a significant influence on care for
COPD patients and subsequent excess costs. The available evidence is heterogeneous and far
from comprehensive for all comorbidities of COPD, but delivers first insights regarding pro-
portion and distribution of comorbid costs. Respectively, the calculated mark-up factors for
different cost types range from 1.5 to 2.5 in the majority of cases and seem to double the costs
on average. As presumed, there were significant differences in the comorbidity specific contrib-
utory extent. Comorbid pneumonia, CVD and diabetes with chronic complications were con-
nected to relatively high excess costs, while comorbid anemia and arthritis were associated with
relatively little cost influence. Main cost driver for comorbidities in all studies was inpatient
cost. Indirect costs were not accounted for, by the majority of studies. Minimizing negligence
of comorbidity associated treatment implications seems warranted and may be realized by ad-
herence to timely updated treatment guidelines. Despite its inherent difficulty, the inclusion of
comorbid influences on COPD should be promoted in future health economic evaluations of
the disease.
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